MEDITE Cancer Diagnostics Appoints Joel Kanter To Its Board As An Independent Director

0 Comments 1 view(s)

ORLANDO, Fla., Nov. 15, 2017 (GLOBE NEWSWIRE) — MEDITE Cancer Diagnostics, Inc. (OTCQB:MDIT) (the “Company”), specializing in the development, manufacturing and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions, today announced the appointment of Joel Kanter to the Company’s Board of Directors as an Independent Director.

Austin Lewis, MEDITE’s Chairman stated, “We are honored to have attracted someone of Joel’s caliber to MEDITE’s Board of Directors and look forward to his contributions during this exciting time in our Company history. Joel has an exceptional track record of impacting change and positive results in both social and corporate endeavors, helping small businesses to grow into larger successful companies as both a financier, as well as an advisor within the healthcare industry. We believe he will be a tremendous asset to MEDITE’s Board moving forward.”

Mr. Kanter commented, “I am excited to join MEDITE’s Board of Directors and to work with the Company to capitalize on the commercial opportunities that lie ahead. The Company is well positioned to expand its commercial portfolio to include innovative products in emerging growth areas such as cytology, and ultimately, personalized medicine, as well as broadening its geographic footprint worldwide. I look forward to supporting this dedicated management team to execute on its growth strategy.”

Mr. Kanter has more than 30 years of experience in the financial services industry, providing financing to businesses ranging from start-ups and early stage development …

Full story available on Benzinga.com